Format
Sealed research vial
Trust signal
COA-backed inventory
99%+ Purity
Lab-grade supply. Limited AU stock.
From A$125.49
Select options below
Size
Select one
Select your preferred options to continue.
Fast AU dispatch, tracked delivery, and documentation-ready inventory.
Why labs buy from APL
High purity, consistent supply, and fast AU-wide dispatch.
Certificate of Analysis
Certificate of Analysis
Verified purity: 99.546%
BPC-157 + TB-500 is a research panel pairing BPC-157 with the thymosin β4 fragment TB-500, studied together in cell-migration, matrix-remodelling, and angiogenic-signalling assay models.
Research panels combining these two peptides often examine matrix remodelling and angiogenic marker expression under well-defined in vitro conditions. Because BPC-157 and TB-500 operate via distinct molecular targets, selectivity controls and appropriate receptor antagonists are important experimental design considerations when the two are studied in parallel.
Browse Inventory
In research literature, BPC-157 + TB-500 is generally treated as a research panel pairing BPC-157 with the thymosin β4 fragment TB-500, studied together in cell-migration, matrix-remodelling, and angiogenic-signalling assay models. BPC-157 is a 15-amino acid pentadecapeptide derived from the partial sequence of human gastric juice protein BPC; in cell-based models it has been studied for interactions with NO/eNOS signalling, VEGFR2-mediated angiogenic pathways, and focal adhesion kinase (FAK)/paxillin complexes relevant to cell-migration assays. TB-500 corresponds to the active fragment of thymosin β4 containing the actin-sequestering LKKTET motif; it binds G-actin with high affinity, reduces the G/F-actin ratio, and modulates cell migration and angiogenesis signalling in scratch-assay models.
Research panels combining these two peptides often examine matrix remodelling and angiogenic marker expression under well-defined in vitro conditions. Because BPC-157 and TB-500 operate via distinct molecular targets, selectivity controls and appropriate receptor antagonists are important experimental design considerations when the two are studied in parallel. For laboratory teams, the practical emphasis is usually on sequence identity, receptor or pathway relevance where documented, and whether BPC-157 + TB-500 behaves consistently across stability, purity, and analytical verification workflows. Variant labels on this page support clearer internal referencing when multiple labelled variants are under review.
Potential research applications for BPC-157 + TB-500 should be framed strictly in analytical and laboratory terms. Typical reasons a team might review this product page include:
Handling decisions should always follow the vial label, internal SOPs, and any product-specific documentation. A conservative laboratory baseline for BPC-157 + TB-500 is:
A product-specific COA is linked on this page, with purity noted as 99.546%. The COA section is useful for confirming how the product is labelled in the catalogue, whether purity information has been published, and whether the laboratory record for the material is complete before bench use.
When teams compare BPC-157 + TB-500 with TB-500, BPC-157, and CJC (NO DAC) + IPA, COA access also helps keep comparator decisions grounded in documented material identity rather than assumption. That is especially important for research pages that combine pricing, variant selection, and analytical records on a single URL.
Certificate of Analysis
Certificate of Analysis
Verified purity: 99.546%
It brings together 2 labelled variants: 10mg and 20mg, current pricing context, stock visibility, COA access, and internal links to related catalogue pages so a laboratory buyer can review the material from a single reference URL.
BPC-157 + TB-500 is generally discussed as a research panel pairing BPC-157 with the thymosin β4 fragment TB-500, studied together in cell-migration, matrix-remodelling, and angiogenic-signalling assay models. The most relevant background is sequence behaviour, pathway or receptor context where documented, and analytical consistency under controlled laboratory conditions.
Use the label, COA, and internal SOPs as the primary guide. In general, store the material under controlled laboratory conditions, minimise avoidable environmental exposure, and keep variant tracking records current.
Yes. This listing includes access to a product-specific COA, which should be reviewed before use so purity, identity, and documentation checks are aligned with the project record.
No. The page should be interpreted strictly in a research and laboratory context. It does not provide dosage guidance, treatment claims, or human or animal use instructions.
